Karyopharm (KPTI) Sell-Off Overdone, Leerink Partners Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Karyopharm Therapeutics (KPTI) Moves to Session Lows
August 10, 2015 2:00 PM EDTKaryopharm Therapeutics (NASDAQ: KPTI) has moved to session lows following Q2 results reported before markets opened Monday. Shares are down over 39 percent and reached a 52-week low at $13.36 today. Volume at over 1.7 million shares compares with average daily volume of about 335,000 shares.
KPTI... More
Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 15c
August 10, 2015 7:41 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.92), $0.15 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $150 thousand versus the consensus estimate of $90 thousand.
Financial Outlook
Based on current operating plans, Karyopharm expects that its existing... More
